Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cell Kathy Ka-Wai AuyeungJoshua Ka-Shun Ko PRECLINICAL STUDIES 13 January 2009 Pages: 1 - 13
INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model R. GraeserN. EsserF. Kratz PRECLINICAL STUDIES 08 January 2009 Pages: 14 - 19
Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II Ahad A. SadiqManish R. PatelRobert A. Kratzke Preclinical Studies 10 January 2009 Pages: 20 - 25
B5, a novel pyrrole-substituted indolinone, exerts potent antitumor efficacy through G2/M cell cycle arrest Xishan XiongYingwei ZhangChanglin Mei PRECLINICAL STUDIES 13 January 2009 Pages: 26 - 34
A novel DNA intercalator, butylamino-pyrimido[4′,5′:4,5]selenolo(2,3-b)quinoline, induces cell cycle arrest and apoptosis in leukemic cells M. S. ShahabuddinMridula NambiarSathees C. Raghavan PRECLINICAL STUDIES 14 January 2009 Pages: 35 - 48
Differential gene expression triggered by highly cytotoxic α-Emitter-immunoconjugates in gastric cancer cells Christof SeidlMatthias PortMichael Abend PRECLINICAL STUDIES 13 January 2009 Pages: 49 - 60
Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents Anthe S. ZandvlietMats O. KarlssonAlwin D. R. Huitema PHASE I STUDIES Open access 06 February 2009 Pages: 61 - 75
Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics Nicolas PenelJean-Pierre DelordJacques Bonneterre PHASE I STUDIES 10 February 2009 Pages: 76 - 82
Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial Keun Seok LeeJungsil RoKyung Hwan Shin PHASE II STUDIES 20 February 2009 Pages: 83 - 90
A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503 Anne M. TraynorJu-Whei LeeJoan H. Schiller PHASE II STUDIES 24 February 2009 Pages: 91 - 97
Esophageal ulcer in a patient who received bevacizumab Judith Meza-JuncoClarence WongMichael B. Sawyer SHORT REPORT 31 March 2009 Pages: 98 - 101
Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report Andrea GombosHassan IzzedineJean-Charles Soria SHORT REPORT 03 April 2009 Pages: 102 - 105